The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 74, Issue 7, 2015, Pages 1474-1478

  Alexander, Tobias ^a,b   Sarfert, Ramona ^c   Klotsche, Jens ^b   Kühl, Anja A ^a   Rubbert Roth, Andrea ^d   Lorenz, Hannes Martin ^e   Rech, Jürgen ^c   Hoyer, Bimba F ^a,b   Cheng, Qingyu ^a,b   Waka, Aderajew ^a,b   Taddeo, Adriano ^a,b   Wiesener, Michael ^c   Schett, Georg ^c   Burmester, Gerd Rüdiger ^a   Radbruch, Andreas ^b   Hiepe, Falk ^a,b   Voll, Reinhard E ^c,f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOUBLE STRANDED DNA ANTIBODY; INTERFERON; PROTEASOME; PROTEASOME INHIBITOR; SIALOADHESIN; VACCINE; ANTIBODY; BORONIC ACID DERIVATIVE; DNA; PYRAZINE DERIVATIVE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG WITHDRAWAL; FEVER; FLOW CYTOMETRY; HEADACHE; HUMAN; INFECTION; MAINTENANCE THERAPY; MONOCYTE; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL LYMPHOCYTE; PLASMA CELL; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM; SKIN ALLERGY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GERMANY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METABOLISM; MULTICENTER STUDY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTIBODIES; BORONIC ACIDS; BORTEZOMIB; DEXAMETHASONE; DNA; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PLASMA CELLS; PROTEASOME INHIBITORS; PYRAZINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84934975828     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206016     Document Type: Article

References (20)

1. Hiepe F, Dorner T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011;7:170-8.
2. Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013;382:819-31.
3. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
4. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
5. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67:1783-92.
6. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14:748-55.
7. Seavey MM, Lu LD, Stump KL, et al. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol 2012;12:257-70.
8. Ichikawa HT, Conley T, Muchamuel T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 2012;64:493-503.
9. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008;86:1754-61.
10. Walsh RC, Alloway RR, Girnita AL, et al. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 2012;81:1067-74.
11. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008;58:1136-45.
12. Rose T, Grutzkau A, Hirseland H, et al. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2013;72:1639-45.
13. Cheng Q, Mumtaz IM, Khodadadi L, et al. Autoantibodies from long-lived 'memory 'plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis 2013;72:2011-7.
14. Tokoyoda K, Hauser AE, Nakayama T, et al. Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 2010;10:193-200.
15. Hirai M, Kadowaki N, Kitawaki T, et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011;117:500-9.
16. Dimopoulos MA, Orlowsky RZ, Facon T, et al. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica 2015;100:100-6.
17. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-40.
18. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947-59.
19. Kortuem KM, Stewart AK. Carfilzomib. Blood 2013;121:893-7.
20. Wang M, Martin T, Bensinger W, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122:3122-8.